Xeris Biopharma Holdings

ISIN US98422E1038

 | 

WKN A3C4ZC

Market cap (in EUR)
1,316 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 1,316 m
EPS, EUR -0.09
P/B ratio 97.6
P/E ratio 123.8
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 259 m
Net income, EUR 0 m
Profit margin 0.19%

What ETF is Xeris Biopharma Holdings in?

There are 3 ETFs which contain Xeris Biopharma Holdings. All of these ETFs are listed in the table below. The ETF with the largest weighting of Xeris Biopharma Holdings is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.10%
Equity
United States
Health Care
Biotech
67
Vanguard Russell 2000 U.S. Small-Cap UCITS ETF USD Dist 0.03%
Equity
United States
Small Cap
3
WisdomTree Russell 2000 0.03%
Equity
United States
Small Cap
7
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.